Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies.

PRNewsWire • May 1, 2026

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Apr 30, 2026

Russell 2000 Rips To Record High — Here Are The Top Small Cap Gainers

The small-cap Russell 2000 punched through to an intraday record high on Friday, capping a furious 13-day rally that marks the index's best run since 2020 and signaling that gains are finally broadening beyond the mega-cap tech leaders.

Benzinga • Apr 17, 2026

Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.

Zacks Investment Research • Apr 1, 2026

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025.

PRNewsWire • Mar 31, 2026

Kodiak Sciences: Road To $120

Kodiak Sciences' stock (NASDAQ: KOD) experienced a substantial 62% surge last week, elevating the stock to $37 and increasing its market capitalization to $2.3 billion. This impressive momentum was fueled by robust Phase 3 GLOW2 results for Zenkuda (tarcocimab), an experimental treatment aimed at retinal vascular disorders.

Forbes • Mar 30, 2026

Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?

Investors appear to be responding to both the strength of the data and the possibility of a faster path toward a biologics license application, or BLA. Here's what investors need to know.

Benzinga • Mar 27, 2026

KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate

Kodiak Sciences rallies 75% as phase III GLOW2 data show Zenkuda's strong efficacy, safety and risk reduction in diabetic retinopathy patients.

Zacks Investment Research • Mar 27, 2026

Kodiak Sciences shares surge after eye drug succeeds in late-stage study

Shares of drug developer Kodiak Sciences jumped 52% before the bell on Thursday after its experimental ​drug met the main goal in a ‌late-stage study in patients with diabetes-related eye damage.

Reuters • Mar 26, 2026

Kodiak Sciences stock soars over 60%: what's behind the sharp rally

Shares of Kodiak Sciences surged sharply on Thursday after the biotechnology company reported positive results from a late-stage study of its experimental drug for diabetic retinopathy, a diabetes-related eye condition. The stock jumped as much as 68.6% to its highest level in more than four years, reflecting strong investor optimism following the announcement.

Invezz • Mar 26, 2026